Ecallantide

N/A

Report date: 2022/01/14 13:23:58
First In Class

Base Information

Drug NameEcallantide
Drug Alias Name依考兰肽ecalantida艾卡仑肽ecallantidum艾卡拉肽 +[10] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionPlasma kallikrein inhibitors
TargetsPlasma kallikrein
Therapy Area/IndicationsBlood Loss, SurgicalHemorrhageHereditary Angioedema Types I and II +[7] 
Global Approved IndicationsAngioedema
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2009/12/01
Country/TerritoryCanadaUnited StatesPoland +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDyax Pharma
China Registration ClassN/A

Develop Information

Active CompaniesDyax CorpCvie Therapeutics Co Ltd
Inactive CompaniesShireCubist Pharmaceuticals LlcFovea Pharmaceuticals Sa
Active IndicationsAngioedema
Inactive IndicationsBlood Loss, SurgicalHemorrhageHereditary Angioedema Types I and II +[6] 

Other Information

ATC CodeB06AC03
Related LinksWikipediaDrugBankKEGG